Your browser doesn't support javascript.
loading
Screening program for familial hyperchylomicronemia syndrome detection: Experience of a university health system
Masson, Walter; Barbagelata, Leandro; Fleitas, Milagros; Herzkovich, Nicole; Kerschner, Eliana; Rossi, Emiliano; Siniawski, Daniel; Ami, María V.; Nogueira, Juan P..
Afiliação
  • Masson, Walter; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Barbagelata, Leandro; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Fleitas, Milagros; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Herzkovich, Nicole; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Kerschner, Eliana; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Rossi, Emiliano; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Siniawski, Daniel; Hospital Italiano de Buenos Aires. Servicio de Cardiología. Buenos Aires. AR
  • Ami, María V.; Hospital Italiano de Buenos Aires. Servicio de Clínica Médica. Buenos Aires. AR
  • Nogueira, Juan P.; Universidad Nacional de Formosa. Facultad de Ciencias de la Salud. Centro de Investigación en Endocrinología, Nutrición y Metabolismo (CIENM). Formosa. AR
Arch. endocrinol. metab. (Online) ; 67(3): 408-415, June 2023. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1429750
Biblioteca responsável: BR1.1
ABSTRACT
ABSTRACT

Objective:

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and

methods:

A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages (1) Review of electronic records and identification of suspected laboratory cases (triglyceride level ≥ 1,000 mg/dL); (2) Identification of suspected clinical cases (all suspected laboratory cases that had no relevant secondary factors) and application of the FCS score to define probable cases (score ≥ 10); (3) Perform genetic tests in probable cases.

Results:

Globally, 348 suspected laboratory cases (mean age of 49.9 years, 77.3% men) were included. The median triglycerides level was 1,309 mg/dL (interquartile range 1,175-1,607 mg/dL). In total, 231 patients were categorized as suspected clinical cases. After applying the FCS score, 3% of them were classified as "very likely FCS" (probable cases). Four variants of uncertain significance have been identified. No previously reported pathogenic variants were detected.

Conclusion:

This study shows a screening program for the detection of FCS. Although no patient was diagnosed with FCS, we believe that more programs of these characteristics should be developed in our region, given the importance of early detection of this metabolic disorder.


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico / Estudo de rastreamento Idioma: Inglês Revista: Arch. endocrinol. metab. (Online) Ano de publicação: 2023 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico / Estudo de rastreamento Idioma: Inglês Revista: Arch. endocrinol. metab. (Online) Ano de publicação: 2023 Tipo de documento: Artigo